Linnaeus Therapeutics, Inc.
StreetZero Signal 74
About Linnaeus Therapeutics, Inc.
Linnaeus Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small-molecule therapeutics targeting G protein-coupled receptors. The company was founded in 2016 based on discoveries originating at the University of Pennsylvania and launched in partnership with the UPstart incubator at Penn Center for Innovation. It is advancing its lead compound LNS8801 across oncology and healthspan-related indications, with headquarters in Haddonfield, New Jersey.
LATEST FUNDINGPrivate Placement
$3.7M
Announced 2026-11-18
TOTAL RAISED$34.75M
IN THE NEWS
- ๐ Linnaeus Therapeutics, Inc.
- ๐ South Jersey biotech gets $4.5M for melanoma drug trial
- ๐ Linnaeus Therapeutics, Inc. Company Overview, Contact Details & Competitors | LeadIQ
- ๐ Linnaeus Therapeutics Awarded Up to $22 Million from ARPA-H to Advance LNS8801 for Healthspan Preservation - BioSpace
- ๐ Linnaeus Therapeutics - Products, Competitors, Financials, Employees, Headquarters Locations
EMPLOYEES2-10
FOUNDED2016
HQHaddonfield, New Jersey, United States
Industry
Biotechnology
Tags
BiotechnologyOncologyClinical-stageB2B
Investors
Key highlights
- Closed nearly $4.5M addition to Series B to fund next clinical trial and team expansion.
- Awarded up to $22M from ARPA-H to advance LNS8801 for healthspan preservation.
- Lead compound LNS8801 targets GPER for oncology indications with orphan drug and Fast Track status.
- Founded on University of Pennsylvania discoveries and supported by Penn Medicine Co-Investment Fund.
- Total funding reported at approximately $35M with additional non-dilutive grants from NCI and SBIR.
Ask StreetZero about Linnaeus Therapeutics, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account